Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
Genom att skicka in godkänner du våra Användarvillkor
88546 trials found · Page 1 of 4428
-
Massive trial proves mRNA vaccine stops COVID-19
⭐️ VACCINE ⭐️ CompletedThis is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals. The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expand…
Phase: PHASE2, PHASE3 • Sponsor: BioNTech SE • Aim: ⭐️ VACCINE ⭐️
Last updated May 01, 2026 10:10 UTC
-
Gene therapy could cure deafness in kids
⭐️ CURE ⭐️ Recruiting nowThis study is a multicenter, single-arm, open-label Phase I/II clinical trial, which is designed to evaluate the safety, tolerability and efficacy of EHT102 injection in treating congenital hearing loss secondary to biallelic mutations of OTOF (DFNB9).Up to 30 pediatric participa…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Euhearing Therapeutics Co., Ltd • Aim: ⭐️ CURE ⭐️
Last updated Apr 30, 2026 15:51 UTC
-
One-Time gene fix could cure 'Bubble Boy' disease
⭐️ CURE ⭐️ Recruiting nowThis is a Phase I/II trial of in vivo lentiviral gene therapy for treating adenosine deaminase severe combined immunodeficiency (ADA-SCID) using a self-inactivating lentiviral vector (LV) ivlv-ADA to functionally correct the genetic defect. The primary objectives are to evaluate …
Phase: NA • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: ⭐️ CURE ⭐️
Last updated Apr 29, 2026 15:01 UTC
-
One-Time gene therapy could free kids from lifelong blood transfusions
Disease control OngoingThis is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Apr 06, 2026 14:18 UTC
-
Massive oxford vaccine trial shows promise against COVID-19
⭐️ VACCINE ⭐️ CompletedA phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in healthy UK volunteers.
Phase: PHASE2, PHASE3 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 29, 2026 15:15 UTC
-
Oxford COVID-19 vaccine shows promise in early trial
⭐️ VACCINE ⭐️ CompletedA phase I/II single-blinded, randomised, multi-centre study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers aged 18-55 years. The vaccine will be administered intramuscularly (…
Phase: PHASE1, PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 30, 2026 15:49 UTC
-
Single infusion gene therapy offers hope for infants with devastating muscle disease
Disease control CompletedThis is a Phase 3, open-label, single-arm, single-dose, trial of onasemnogene abeparvovec-xioi (gene replacement therapy) in participants with spinal muscular atrophy (SMA) Type 1 and who are genetically defined by a biallelic pathogenic mutation of the survival motor neuron 1 ge…
Phase: PHASE3 • Sponsor: Novartis Gene Therapies • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
CRISPR breakthrough frees patients from lifelong blood transfusions
Disease control CompletedThis is a single-arm, open-label, multi-site, single-dose Phase 1/2/3 study in participans with transfusion-dependent β-thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPC…
Phase: PHASE2, PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
Single infusion offers hope for babies with devastating muscle disease
Disease control CompletedPhase 3, open-label, single-arm, single-dose, trial of onasemnogene abeparvovec-xioi (gene replacement therapy) in patients with spinal muscular atrophy (SMA) Type 1 who meet enrollment criteria and are genetically defined by a biallelic pathogenic mutation of the survival motor …
Phase: PHASE3 • Sponsor: Novartis Gene Therapies • Aim: Disease control
Last updated Apr 07, 2026 14:35 UTC
-
Bubble boy disease gene therapy trial offers hope for a normal life
⭐️ CURE ⭐️ Recruiting nowThis is a phase I/II open label multi-center study in which patients will receive low dose targeted busulfan followed by infusion of autologous CD34+ selected bone marrow or mobilized peripheral blood cells transduced with the G2SCID vector. Subjects will be enrolled over 3 years…
Phase: PHASE1, PHASE2 • Sponsor: David Williams • Aim: ⭐️ CURE ⭐️
Last updated Apr 29, 2026 15:03 UTC
-
One-Time gene therapy helps babies with fatal muscle disease sit and survive
Disease control CompletedPhase 3 pivotal US trial studying open-label intravenous administration of onasemnogene abeparvovec-xioi in spinal muscular atrophy (SMA) Type 1 participants.
Phase: PHASE3 • Sponsor: Novartis Gene Therapies • Aim: Disease control
Last updated May 01, 2026 10:09 UTC
-
One pill to cure sleeping sickness? new trial shows promise
⭐️ CURE ⭐️ CompletedThe goal of this study is to assess efficacy and safety of acoziborole in adult participants with Trypanosoma brucei gambiense (T.b. gambiense) HAT, either early- or intermediate-stage HAT (first arm) or late-stage HAT (second arm). Participants will receive 3 tablets of 320 mg a…
Phase: PHASE2, PHASE3 • Sponsor: Drugs for Neglected Diseases • Aim: ⭐️ CURE ⭐️
Last updated May 01, 2026 10:10 UTC
-
Gene therapy offers hope for boys born without immune systems
⭐️ CURE ⭐️ CompletedX-linked severe combined immunodeficiency (SCID-X1) is an inherited disorder that results in failure of development of the immune system in boys. This trial aims to treat SCID-X1 patients using gene therapy to replace the defective gene.
Phase: PHASE1, PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: ⭐️ CURE ⭐️
Last updated May 01, 2026 10:09 UTC
-
Lab-Grown nerve cells injected into spine could restore movement after paralysis
Disease control Not yet recruitingPurpose: This clinical trial is studying an investigational cell therapy called XS228-a lab-made stem cell product designed to help repair damaged nerves in the spinal cord. The goal is to see if XS228 is safe and can improve movement, sensation, and function in people with recen…
Phase: PHASE2 • Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
New combo therapy targets deadly lymphoma complication
Disease control Recruiting nowExtranodal NK/T-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes with no standard therapy. Notably, 10%-20% of patie…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
Could a smart test guide breast cancer to remission?
⭐️ CURE ⭐️ Recruiting nowThie purpose of this study is to find out whether a personalized treatment approach-using a series of ctDNA tests along with standard imaging scans to help decide when to step up (escalate) or decrease (de-escalate) sequential treatments (given one after another)-combined with lo…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: ⭐️ CURE ⭐️
Last updated Apr 30, 2026 15:51 UTC
-
UCLA pioneers 'Delayed Tolerance' to end lifelong drug use after liver transplant
Disease control Recruiting nowThis clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery. Lifelong use of these drugs is the current standard, but they come with life-threatening side effects. UCLA has pioneered this "Delayed…
Phase: PHASE1, PHASE2 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated May 01, 2026 09:56 UTC
-
Could this combo cure hepatitis b in kids? new trial aims for functional cure
⭐️ CURE ⭐️ Not yet recruitingThis study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-active, HBeAg-positive children aged 3-6 years with chronic hepatitis B.
Phase: PHASE4 • Sponsor: Qing-Lei Zeng • Aim: ⭐️ CURE ⭐️
Last updated Apr 26, 2026 19:36 UTC
-
Pig kidney transplants begin: a lifeline for kidney patients?
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transpl…
Phase: PHASE1, PHASE2 • Sponsor: United Therapeutics • Aim: Disease control
Last updated May 01, 2026 09:56 UTC
-
New combo aims to cure metastatic breast cancer with surgery and targeted radiation
⭐️ CURE ⭐️ Recruiting nowThe researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic HER2-positive breast cancer than the usual approach alone. T…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: ⭐️ CURE ⭐️
Last updated May 01, 2026 10:08 UTC